Why does the debate over the
appropriate treatment of
ductal carcinoma in situ
(DCIS) continue? Three widely publicized
multi-institutional randomized
trials have addressed this question,[1-4]
and all have reached largely the same
conclusion. Radiation therapy reduces
the risk of local recurrence of DCIS
by approximately 50%. Despite this
fact, a significant percentage of DCIS
patients (50% or more in many settings)
in consultation with their clinicians
opt to undergo excision alone
and forgo radiotherapy.
The paper by Silverstein summarizes
the argument for this less aggressive
approach in a clear and straightforward
manner. The major rationale
for this position is that several studies
from single institutions have clearly
shown that the clinical behavior of
DCIS is not the same in all cases and
that, in many situations, the expected benefit from radiotherapy is quite low.
In fact, one of the more remarkable
aspects of DCIS is its profound heterogeneity,[5] seen in its pathology,
mammographic appearance, and clinical
manifestations.
Margin Status
The contention of Dr. Silverstein
that many cases of DCIS do not benefit
from radiation therapy after excision
is undoubtedly true and well supported
by a large body of evidence.
First, the factors involved in local
recurrence after excision of DCIS are
well known and accepted. These include
margin status, grade and pattern of
spread, and overall extent of the individual
DCIS lesion. Of these, margin
status is certainly the most important,[6]
but it is also clear from abundant experience
that larger, higher-grade lesions
with more irregular margins may have
spread in ducts that go unnoticed unless
excision margins are extended to
approximately 1 cm. This means that
the lower-grade, smaller lesions that
often tend to be remarkably rounded and
consist of clustered lobular units and
ducts may require less effort at margin
determination for excision because the
spread of these tumors is more confined
and easily detected.
Case Definition
Dr. Silverstein raises an important
point that has not been addressed specifically
in many studies but is borne
out by excellent supportive evidence.
His point is that larger, high-grade
DCIS lesions must be approached
quite differently from the smaller varieties.[3] Thus, the major misleading
mythology in the treatment of DCIS
is that these lesions are all the same.
Indeed, it is case definition and its precision
that has led some therapeutic
studies somewhat astray.
For example, the final summary of
the important National Surgical Adjuvant
Breast and Bowel Project (NSABP)
B-17 study used mammographic measures
to indicate the size of the lesions.[7] At least 30% of the cases were
not centrally reviewed in this area of
difficult histopathology. Also in this
study, the number of local recurrences
among cases that had not been irradiated
was extremely large-more than
10% at 5 years. This is to be understood
against the backdrop of studies with
careful case definition and a small number
of cases, particularly of low-grade
lesions at 5 years without radiation
therapy. Thus, it is clear that NSABP
B-17 is a study of women who had more
than a 10% local recurrence rate with
or without radiation therapy, and that
experience cannot be compared with
studies of carefully defined, smaller lesions
in which virtually no local recurrences
occurred at 5 and even 10 years
after adequate determination of margin
status at surgical excision without radiation
therapy.
We seem to be discussing two kinds
of studies: those with careful case definition
and individual case follow-up,
and those with poor case definition and
evaluation of overall therapeutic efficacy.
Careful case definition would
seem to be more important for large
studies that are evaluating therapy, in
order to identify patients who do not
need treatment. This would seem preferable
to showing that the treatment is
effective in a certain percentage of cases
and then averaging all the cases, including
many that did not need the therapy.
The design of the other important
large, multicenter trial performed in
Europe had similar drawbacks, and this
trial found some recurrences of highgrade
invasive cancers-even some
cases with lymph node metastases. Most
importantly, the majority, if not all, of
these life-threatening local recurrences
developed among patients who initially
had high-grade DCIS.[3]
At this time, we must recognize that
case definition and the precise histologic
character of excised lesions must
be documented.[8] It is also clear from
several studies that low-grade lesions
may have smaller margins than 1 cm,
but the proof of principle for Dr.
Silverstein, Dr. Lagios, and their colleagues-
that any DCIS excised to
a 1-cm margin should have no untoward
consequences without radiation
therapy-represented a banner moment
in this controversy.
Conclusions
In summary, thousands of women
have been treated for DCIS with surgical
excision to negative margins and
careful, continued mammographic follow-
up. The rates of local recurrence are
small (often 0% at 5 to 8 years), particularly
among patients with low-grade
and smaller lesions (less than 1 to 1.5 cm
in size). Also, the rare local recurrences
are regularly similar in grade, unless
residual disease remains untended for
a prolonged number of years.[9] Many
centers in North America and Europe
are treating one-half or more of their
DCIS patients in this conservative
manner. The nature and rate of recurrences
elsewhere in the treated breast
(not in the original segment or quadrant)
or in the contralateral breast are
less well understood, are analogous to
disease in the contralateral breast after
a mastectomy, and should be regarded
as separate events.
In stark contrast, the cases of excised
DCIS not treated further by radiation in
the large NSABP and European Organization
for Research and Treatment of
Cancer (EORTC 10853) trials have had
local recurrence rates of 10% or more.
Although the local recurrences in patients
with low-grade lesions probably
pose little threat to life, it is also clear
that, even with radiation, recurrences of
high-grade lesions may be associated
with invasive cancer of a life-threatening
nature. Clearly, precise case definition
including evaluation of margins
should be mandatory in individually
treated women (as well as in any further
trials conducted in this disease). It
is also important to detail the size, grade,
and invasive nature of local recurrences
rather than to simply regard a "local
recurrence" as an event not mandating
further definition.
